UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2577138 | --- | --- | --- | |------ ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q2 2024 Earnings Conference Call August 14, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Conference Call Participants Hunter Diamond - Diamond Equity Noella Alexander-Young Hello and good morning, everyone. Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications. On behalf of our team we want to thank everyone f ...

Exhibit 99.1 ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2024 Company Anticipates Significant Sequential Growth in Quarterly Revenues Beginning in Q3 2024 and Beyond Reports Pharmaloz Growth Acceleration Has Begun in Q3 2024 and Potential Sale of Business Announces Major DTC Initiatives for Nebula Genomics, anticipating new sales ramp in Q4 2024 Company to hold a virtual conference call Wednesday, August 14, 2024, at 11:00 AM ET GARDEN CITY, NY, August 14, 2024 (GLOBE NEWSW ...

GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on August 14, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participa ...

PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. The Company also anticipates the arrival of new manufacturing equipment for its second lozenge manufacturing line in the current fiscal quarter. This could more than double production capacity, thereby allowing PMI to meet the growing demand of current and potential new customers. The Company believes that the additional capacity of the second line, plus new product offerings, provide opportunities to gr ...

PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. Based on these improvements and the expectation of continued increasing customer demand, the Company believes that beginning in the current Q3 2024, PMI's 12-month forward looking revenue run rate with one production line will be approximately $14-16 million and approximately $5 million in pre-tax net profits. These results are anticipated solely through operation of PMI's first enhanced manufacturing li ...

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ:PRPH). The update note includes information on the ProPhase's business model, services, industry, financial results, valuation, and risks. The update note is available here. Highlights from the note include: Operational Updates and Growth Catalysts for ProPhase Labs' Diverse Business Portfolio - ProPhase La ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) | Delaware | 23-2577138 | | --- | --- | | (Sta ...

Financial Data and Key Metrics - Revenue from existing business increased from $9.3 million to an annualized run rate of $16 million, with profits expected to be around $3.5 million [4] - Adjusted EBITDA and cash flow improved significantly in Q1 2024 compared to Q4 2023 [31] Business Line Data and Key Metrics - Pharmaloz is expected to see significant improvement in the second half of 2024, with full capacity demand for Q3 [26] - Nebula Genomics is projected to ramp up revenues in Q4 2024 or Q1 2025, with substantial potential in its bioinformatics platform and database [3][61] - Equivir, a dietary supplement, completed a study with over 300 patients, showing promising results in reducing illness from viruses like COVID, flu, and RSV [18][30] Market Data and Key Metrics - Pharmaloz has attracted potential new customers, including smaller brands that could fill up the second manufacturing line [6] - The BE-Smart Esophageal Cancer test targets a market of 7 million endoscopies annually, with potential insurance reimbursement of $1,000 to $2,000 per test, creating a $7 billion to $14 billion market [74] Company Strategy and Industry Competition - The company is exploring strategic alternatives for Pharmaloz, including potential sales or partnerships, after 1.5 to 2 years of planning and execution [5][29] - Nebula Genomics is developing a new go-to-market strategy leveraging social media and podcast experts, with potential celebrity endorsements [61][75] - The BE-Smart test is positioned as a breakthrough in cancer diagnostics, with no direct competition and multibillion-dollar potential [52][97] Management Commentary on Operating Environment and Future Outlook - Management believes the company is at a turning point, with significant developments expected in Pharmaloz, Nebula, and the BE-Smart test [28][40] - The company is focused on long-term value creation for shareholders, with no immediate plans for equity financing [23][103] - The lab infrastructure for Nebula Genomics is seen as a strategic asset, despite current costs, due to its potential for future growth [51][110] Other Important Information - The company has a history of successful turnarounds, including the sale of Cold-EEZE for $50 million and IT Biomedical for $1.4 billion [63] - The AI initiative leverages the company’s database and proprietary discoveries, focusing on anti-drug conjugates for cancer treatment [78] Q&A Session Question: Growth plans for Nebula Genomics - Nebula’s growth strategy includes leveraging its bioinformatics platform, database, and social media experts, with revenues expected to ramp up in Q4 2024 or Q1 2025 [61][75][116] Question: Potential IPO for Nebula or Pharmaloz - The company is open to IPOs for Nebula or Pharmaloz under the right market conditions but is cautious about timing to maximize valuation [22][109] Question: Revenue expectations for Q2 2024 - Management does not expect significant revenue growth in Q2, with major improvements anticipated in Q3 for Pharmaloz and Q4 for Nebula [31][87] Question: Claims for Equivir packaging - Claims for Equivir are still being finalized, with the company planning to launch the product online first before expanding to retail stores [86][118] Question: Valuation of CDMO sales licensing transactions - The company declined to provide additional information on CDMO valuation, citing ongoing strategic discussions [24] Question: Potential partnership for BE-Smart - The company is open to exploring partnerships for BE-Smart but is focused on maximizing long-term shareholder value [32][36] Question: Share count increase from 18 million to 90 million - Management did not provide specific details on the share count increase, only noting that shares change over time [111]

Exhibit 99.1 ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. Pharmaloz Manufacturing explores strategic alternatives, including potential sale. Company announces major strategic AI initiative, Project ZenQ-AI, leveraging its massive global genomics database and patented discoveries in its BE-Smart Esophageal Cancer Diagnostic Test. BE-Smart Cancer Test continues to advance towards second half commercializa ...